Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. entered a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies using CytomX’s Probody therapeutic platform and Regeneron’s Veloci-Bi bispecific antibody development platform.   The collaboration is strategically focused on applying CytomX’s biologic masking strategies to develop investigational Regeneron bispecifics that remain inactive until activated ...